Introduction
The Met tyrosine kinase is a high-anity receptor for hepatocyte growth factor/scatter factor (HGF/SF) . Both Met and HGF/SF are expressed in numerous tissues, although their expression is con®ned predominantly to cells of epithelial and mesenchymal origin, respectively (Stoker et al., 1987; Sonnenberg et al., 1993) . Signaling via this receptorligand pair has been shown to aect a wide range of biological activities, including angiogenesis (Bussolino et al., 1992; Grant et al., 1993) , cellular motility (Stoker et al., 1987) , growth (Higashio and Shima, 1993; Nakamura et al., 1986; Rubin et al., 1991) , and morphogenic dierentiation (Montesano et al., 1991; Brinkmann et al., 1995; Tsarfaty et al., 1992) . In addition to mediating a variety of normal cellular processes, Met-HGF/SF signaling has also been implicated in tumorigenesis and metastasis (reviewed in Jeers et al., 1996d) . Several oncogenic forms of Met have been discovered. The tpr-Met oncogene was originally discovered as an activated form of the Met receptor, and represents the fusion of two distinct genetic loci (Cooper et al., 1984; Park et al., 1986; Rodrigues and Park, 1993) . It is also oncogenic when the native unaltered receptor is subjected to autocrine stimulation by HGF/SF (Bellusci et al., 1994; Jeers et al., 1996b,c; Kanda and Kitagawa, 1993; Rong et al., 1992) . In addition to mediating transformation in model systems, Met-HGF/SF signaling plays a role in human cancer (reviewed in Jeers et al., 1996d) . Recently, missense mutations in the tyrosine kinase domain of Met have been found to be oncogenic and able to induce metastasis . These mutations were originally found in hereditary and sporadic human papillary renal carcinomas , and were shown to cause constitutive activation of Met tyrosine kinase activity. While the majority of mutations in Met have been discovered in papillary renal carcinoma Olivero et al., 1999) , mutant Met molecules have been reported in one case of ovarian cancer (Tanyi et al., 1999) , and in three of 10 childhood hepatocellular carcinoma . To date, all of the activating mutations in Met have been identi®ed as missense mutations in the tyrosine kinase domain.
Non-random duplication of chromosome 7 (trisomy 7) has been observed in tumors of individuals with germline activating mutant Met alleles, and has been proposed as a mechanism responsible for progression to hereditary papillary renal cancer . We noted that trisomy of chromosome 7 is frequently observed in primary gastric adenocarcinoma (40%) (Rao et al., 1993; Matturri et al., 1998 ).
Here we examined primary gastric adenocarcinomas for Met mutations in six exons (14, 16 ± 20) , and found an activating Met mutation, P1009S, that was germline in the patient, and ampli®ed in the tumor. This is the ®rst activating mutation discovered in the Met juxtamembrane domain. While P1009S Met is not constitutively activated, as we ®nd in Met molecules with mutations in the tyrosine kinase domain, this juxtamembrane mutant Met molecule appears to be oncogenic by a dierent mechanism, and after HGF/ SF treatment, the receptor remains tyrosine phosphorylated for 24 ± 48 h.
Results
We screened 85 cases of primary gastric cancer for Met mutations. Among the 21 exons of Met, we focused on one exon coding for the juxtamembrane domain with a regulatory site (Gandino et al., 1994; Villa-Moruzzi et al., 1998) (exon 14) , and ®ve exons from the tyrosine kinase domain where all other mutations in Met have been discovered (exons 16 ± 20) .
We used DHPLC as a screening method for identifying mutations in the genomic DNA PCR products ( Figure 1 ). All products showing an additional peak were bi-directionally sequenced. Samples with discrete additional sequence(s) were selected and subjected to`cold SSCP'. The additional SSCP band(s) were re-ampli®ed with the same primers and sequenced ( Figure 1 ). We found a missense mutation in exon 14 (P1009S) in a gastric cancer specimen (C3219T as in Figure 1 ). This mutation was also present in normal blood DNA from this patient, and therefore, is germline. However, this mutation was not found in 135 normal individuals of Korean ethnicity.
We also screened 30 breast cancer samples and found one tumor with a missense mutation, also in the juxtamembrane domain (C3223T: T1010I), and adjacent to the P1009S mutation. The T1010I mutation was also in the DNA from a tumor cell-negative lymph node of this individual, indicating it was also germline. This mutation was previously identi®ed in a tumor biopsy of hereditary renal papillary cancer and a papillary renal cancer cell line, ACHN, and appeared to be a polymorphism . We screened 50 additional tumor cell lines for mutations in exon 14, and detected a C to T sequence change at nt 3223 (T1010I) in a large cell lung cancer cell line, Hop-92.
To address whether these mutations displayed biological activity, the exon 14 Met mutations were introduced into Met cDNA, and these cDNAs were transfected into NIH3T3 cells . Cells transfected with wild-type and mutant Met constructs expressed comparable levels of exogenous Met protein. A previously characterized weak germline mutation, M1149T, found in a hereditary renal papillary cancer patient Jeers et al., 1997) was used as a control, which has a lower level of expression in NIH3T3 cells (Figure 2 ). The mutant Met molecules were also compared to the potent M1268T mutant, found in a sporadic renal papillary cancer Jeers et al., 1997 Jeers et al., , 1998 . In the absence of the exogenous HGF/SF, the kinase activity of the P1009S and T1010I Met protein were not signi®cantly dierent from wild-type Met (Figure 2 ). However, we observed a signi®cant Figure 1 Scheme for the screening and con®rmation of c-Met mutations. Genomic DNAs extracted from tissues were subjected to PCR ampli®cation using each exon-speci®c primer pair . The PCR products were analysed by DHPLC. The samples showing additional peaks in the chromatogram were further analysed by double-strand sequencing, using the same primers used in PCR ampli®cation. A few samples clearly showed two distinct peaks at one site. For those samples,`Cold' SSCP was performed, in which the bands were excised and re-ampli®ed using the same primers used for the ®rst ampli®cation. Bi-directional sequencing was performed to con®rm the mutation. All data presented are for the P1009S mutant dierence in anti-phosphotyrosine reactivity between P1009S mutant Met and wild-type Met after treatment with HGF/SF ( Figure 3 ). Whereas P1009S was only slightly higher than T1010I and wild-type Met after 0.2 h, the signal for P1009S persisted even after 24 h ( Figure 3b and data not shown). Thus, the P1009S mutant displays prolonged tyrosine phosphorylation in response to HGF/SF, while the T1010I mutation appears to be equivalent to wild-type.
Germline Met mutations are less active biologically and biochemically when compared with sporadic Met mutations . Neither the P1009S nor the T1010I mutant Met molecules phenotypically transformed NIH3T3 cells (data not shown), nor were they active in the focus-forming assay (data not shown). However, in soft agar colony formation assays, we observed signi®cant numbers of colonies with cells containing the P1009S mutant Met DNA (Figure 4 ). The T1010I mutant containing cells did not show signi®cant growth in soft agar (Figure 4) .
The nude mouse assay is the most sensitive assay for detecting oncogenic activity Blair et al., 1983) . We therefore tested NIH3T3 cells expressing each of the mutant Met proteins for tumorigenicity in athymic nude mice. Each of the cell lines expressing mutant Met proteins formed tumors more readily than cells expressing wild-type Met (Table 1 ). The novel juxtamembrane P1009S mutant displayed signi®cant tumorigenic activity, and even the T1010I mutant developed tumors 32 days after injection, slightly faster than the wild-type Met expressing cells. As expected, the cells expressing the most active mutant Met molecule, M1268T, rapidly formed tumors (Table 1) . Jeers et al. (1997) observed that the level of Met expressed in explants derived from tumors displayed an inverse correlation with enzymatic activity and biological activity. An examination of Met expression in the explants of P1009S and T1010I NIH3T3 cells revealed that the explanted cells expressed signi®cantly higher levels of Met than the parental pools of cells used in the inoculum ( Figure 5 ). The T1010I explant Met levels were similar to the levels in the wild-type explant, but less Met was observed in P1009S explants, and as observed previously, M1268T explants express the lowest levels of Met . These ®ndings are consistent with the agarose colony formation assay, suggesting the order of biological activity of the mutant Met molecules is M1268T44 P1009S4M1149T4T1010I5WT.
Non-random duplication of the chromosome bearing mutated Met molecules occurs in hereditary renal carcinoma . We measured the relative abundance of mutant Met DNA in two dierent samples of the gastric tumor from the same patient (T28; T47), compared to matched normal DNA. The P1009S mutation generates a new AluI restriction enzyme site, and digestion of PCR product by AluI enzyme showed two new bands (106 and 44 bp) derived from the expected 150 bp molecule. The ratios of the intensities of the 106 and 44 bp bands were measured by a phosphoimager relative to an 85 bp Met band that is present in both mutant and wild-type DNA, which showed little sample-to-sample variation because of the large number of ampli®cation cycle used. The mutant bands were 1.35 ± 1.6-fold higher in the tumor than normal tissue (Figure 6 ). Considering contamination of the tumor tissue with normal stromal cells, the data indicates that a higher percentage of the P1009S mutant DNA is present in the tumor.
Discussion
Stomach cancer is one of the most common cancers worldwide, and is responsible for almost 10% of all new cancer cases with marked geographic and ethnic variation in incidence and mortality (Pisani et al., 1999) . As for the etiology of stomach cancer, environmental factors such as H. pylori infection and oral intake of carcinogens are known to be involved. However, it has recently been reported that a subset of familial gastric cancer is associated with germ line E- Figure 6 Comparison of the relative amount of mutant DNA from normal (N) and tumor (T) tissue. Independent DNA samples obtained from tumor (T47 and T28) and normal (N47 and N28) tissues were analysed after PCR-ampli®cation using exon14-speci®c primers in the presence of 1 uCi of 32 PdCTP(Amersham). After the PCR reaction, the products were digested with AluI restriction enzyme, and subjected to electrophoresis in a 20% polyacrylamide gel. Autoradiography was performed using a phosphoimager plate (Molecular Dynamics). The 150 bp band is cut into 106 and 44 bp bands in P1009S mutant. The relation to the amount of mutant DNA in the genomic DNA samples was calculated as intensity of 106 bp and 44 bp bands relative to the intensity of 85 bp band cadherin/CDH1 mutations (Guilford et al., 1998 (Guilford et al., , 1999 Caldas et al., 1999) . We have previously proposed that E-cadherin and catenin molecules might function downstream of Met , and Papko and Aikawa (1998) and Tsarfaty et al. (1992) have demonstrated Met dependent signaling through B-catenin and E-cadherin. Moreover, Met has been shown to be over-expressed in several human gastric carcinoma cell lines Ponzetto et al., 1991) . This suggests that MET may be responsible for tumorigenesis of both familial and sporadic gastric cancer. The germline P1009S mutation, which is not present in 135 normal individuals, is likely to cause gastric cancer in this patient as it demonstrates transforming activity in athymic nude mice and increases in dosage in the tumor biopsy. The latter is in agreement with the selective enhancement for Met found in all model systems of Met tumorigenesis and metastasis (Rong et al., 1992; Jeers et al., 1996a) including familial papillary renal cancer.
The role of the juxtamembrane region of Met in cell transformation is unknown, and the mechanism(s) by which P1009S mutant activates the transforming potential of the Met receptor is not clear. Adding the juxtamembrane domain to tpr-Met fusion protein abolishes its transforming activity (Vigna et al., 1999) . Two sites within this region have been described as regulatory sites. S1003 (Figure 7 ) was described as a substrate of protein kinase C (PKC), and its phosphorylation results in the down regulation of tyrosine kinase activity of c-Met (Gandino et al., 1994) . In addition, a speci®c protein tyrosine phosphatase (PTP-S) is reported to bind to this region (Figure 7 ) (Villa-Moruzzi et al., 1998) , as well as a PEST sequence, which could potentially serve as a site for ubiquitination, is also present at the juxtamembrane domain (Figure 7 ) (Crepaldi et al., 1994) . We observed no dierences in the amount of wild-type and P1009S Met protein in the absence of ligand. However, after HGF/SF treatment, the P1009S Met mutant molecules reactivity with phosphotyrosine antibody persists for more than 24 h, and signi®cantly longer than wild-type Met. This suggests that the down regulation of Met, which occurs after receptor activation and tyrosine phosphorylation is impaired by this mutation.
T1010I mutant was previously reported in a papillary renal carcinoma cell line and in the germline of a patient with a family history of papillary renal carcinoma, but was considered as a polymorphism as it did not segregate with the disease in the family. We detected T1010I in a primary breast cancer sample, and in a large cell lung cancer cell line, Hop-92. When it was introduced into NIH3T3 cells, it did not show focus formation and neither did it cause constitutive Met phosphorylation . We make the same observation here also. However, in athymic nude mice, tumors formed slightly faster with T1010I than with wild-type Met. Therefore, it is possible that the T1010I mutation might have eects on tumorigenesis, especially in an autocrine environment since NIH3T3 cells produce HGF/SF (Rong et al., 1992) .
Materials and methods

Tumor tissues and blood
The study included a panel of 85 pairs of gastric carcinoma DNA and matching normal DNA, which were obtained from the Ajou University Hospital (Korea). The normal was extracted from either normal gastric tissue recovered during gastrectomy, or from patients' blood. The 30 breast cancer DNA samples were obtained from Norfolk and Norwich Hospital (UK). Blood samples from 135 normal individuals were obtained and analysed at the Ajou University Hospital (Korea) for the germline mutation found in the above to establish if it is a polymorphism in the Korean population. Finally, we also screened for mutations in 50 tumor cell lines of the following origin: stomach, lung, kidney, prostate and skin.
Mutation analysis of the MET gene
DNAs were screened for mutations in exons 14, and 16 ± 20 in the MET proto-oncogene by denaturing high performance liquid chromatography (DHPLC). The primers used have been described elsewhere . DHPLC was performed as described (Underhill et al., 1997) . PCR products were run on a Varian/Rainin machine using a DNASep column (Transgenomics, San Jose, CA, USA). Samples were run in 0.1 M TEAA pH 7.0 buer containing 17% acetonitrile. The latter was then raised to 30.5% at 1 min, to 34% over the next 4 min and to 50% for the last 2 min. Melting temperatures for heteroduplex formation between mutant and wild-type strands of the PCR products were calculated using a program developed by Peter Oefner, which is available at http://hardy-weinberg.stanford.edu/ dhplc/melt.html. PCR products from samples that showed an aberrant peak in DHPLC chromatogram were bidirectionally sequenced. In addition, to dierentiate between a true mutation and artifact, non-radioactive SSCP (`cold SSCP') (Hongyo et al., 1993) analysis of the PCR product was also performed on pre-cast 4 ± 20% TBE mini gels using the Thermo¯ow vertical electrophoresis system (Novex) according to the manufacturer's instructions. Aberrant migrating bands were excised and DNA was recovered using Qiaex II gel extraction kits (Qiagen) according to the manufacturer's instructions. Extracted DNA was re-ampli®ed using the same set of original primers and bi-directionally sequenced.
NIH3T3 transformation assay
NIH3T3 cells (CRL1658) were obtained from the American Type Culture Collection, and cultured in DMEM (Life Figure 7 Amino acid sequence of the juxtamembrane domain of Met. The PT residues shown in white on black are the sites of the P1009S and T1010I mutations, respectively. Phosphorylation of S1003 (*) by PKC results in down-regulation of receptor tyrosine kinase activity (Gandino et al., 1994) . The shaded box denotes the binding site of PTP-S (Villa-Moruzzi et al., 1998) . Bold underscore denotes the PEST sequence (Crepaldi et al., 1994) Technologies) containing 10% calf serum (CS) (Life Technologies). These cells produce only two scatter units/ml of HGF/SF, a level signi®cantly lower than other NIH3T3 sub-lines we have previously analysed .
The wild-type Met expression vector (called PMB11) contains the murine Met cDNA in PMB1 as described previously . To construct the Met mutants, the Quick Change site-directed mutagenesis kit (Stratagene) was used according to the manufacturer's instructions. Mutations were veri®ed by sequencing both strands of DNA.
Following this, transfections and focus-forming activity assays were performed as described previously . In addition, agarose colony generation assay was performed as follows. Noble agar solution (3.5% W/V in PBS) pre-warmed at 438C was added to DMEM containing 10% FBS pre-warmed at 378C to make 0.8% agar. After rapid mixing by inversion, the resultant solution was added to 24-well plates at a volume of 0.5 ml/well. The transfected cells, at 70 ± 80% con¯uency, were trypsinized, washed with PBS three times, and diluted in 0.4% (W/V) Noble agar solution (0.4% Noble agar in DMEM with 10% FBS) at 378C. The suspended cells were added to each well (1500 cells/0.4 ml/well) with 0.8% agar layer. Plates were incubated at 378C in 5% CO 2 for 6 ± 8 weeks. Once weekly, 0.4% Noble agar in DMEM with 10% FBS was added (0.3 ml/well) to provide required nutrients and growth factors.
MET phosphorylation and expression studies
The transfected cells were used and Western analyses were performed as previously described (Jeers et al., 1996c) under reducing conditions using the following primary antibodies: anti-Met (SP260; Santa Cruz Biotechnology), and antiphosphotyrosine (clone 4G10; Upstate Biotechnologies Inc.). For immunoprecipitation, monolayers of stably transfected cells were washed twice with ice-cold PBS, lysed in ice-cold RIPA buer consisting of 10 mM sodium phosphate (pH 7.2), 150 mM NaCl, 1% (W/V) Nonidet P-40, 0.1% (W/V) SDS supplemented with 10 mM sodium uoride, 5 mM sodium orthovanadate, and complete protease inhibitor cocktail (Boehringer Mannheim) and centrifuged for 15 min (48C, 14 000 r.p.m.). After quanti®cation using the BCA protein assay reagent (Pierce), 400 mg of each lysate was pre-cleared with protein A Sepharose and incubated with anti-Met antibody (SP260; Santa Cruz Biotechnology) and protein A Sepharose overnight at 48C. The samples were washed three times with ice-cold RIPA buer and suspended in SDS gel-loading buer. After boiling (5 min) and centrifuging (5 min, 14 000 r.p.m.), the resulting supernatants were resolved by SDS ± PAGE and examined by Western analysis.
In vivo tumorigenesis assay Pools of G418-resistant NIH3T3 cells expressing the indicated Met proteins were generated as described above, and were shown by Western analysis to express nearly equal amounts of exogenous Met protein. The cells were prepared as previously described , and 5610 5 cells were inoculated subcutaneously into 4-week-old female athymic nude mice. Tumor cell explant cultures were established as follows: 200-to 400-mm 2 tumors were minced and cultured in DMEM/10% CS supplemented with 800 mg/ ml G418.
DNA dosage analysis
Tumor and normal DNAs harboring P1009S mutant were ampli®ed in the presence of 1 mCi of 32 P-dCTP/tube by using the same PCR primers as for mutation screening of exon 14 (Amersham). Since the P1009S mutation gives a new AluI enzyme restriction site, the PCR products were digested with AluI restriction enzyme. After the completion of digestion, samples were subjected to electrophoresis by using 4 ± 20% or 20% polyacrylamide gel in TBE buer. After electrophoresis, the gel was dried and subjected to autoradiography using a phosphoimager (Molecular Dynamics). The intensities of each band were measured.
Abbreviations DMEM, Dulbecco's modi®ed Eagle's medium; FBS, fetal bovine serum; PCR, polymerase chain reaction; PKC, protein kinase C; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformation polymorphism; TBE, tris-buered EDTA.
